机构:[1]Ben May Department for Cancer Research, The University of Chicago, Chicago,IL, USA[2]Department of Pharmaceutical and Biomedical Sciences, University ofGeorgia, Athens, GA, USA[3]College of Pharmacy, Research Institute ofPharmaceutical Sciences, Kyungpook National University, Daegu, South Korea[4]Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada[5]Department of Biological Chemistry and Pharmacology, The Ohio StateUniversity, Columbus, OH, USA[6]CNRS UMR 5309, INSERM, U1209, UniversitéGrenoble Alpes, Institute for Advanced Biosciences, Grenoble, France[7]Shanghai Institute of Materia Medica, Chinese Academy of Sciences,Shanghai, China[8]Department of General Practice, State KeyLaboratory of Biotherapy, West China Hospital, Sichuan University, andCollaborative Innovation Center of Biotherapy, Chengdu, China四川大学华西医院
University of Chicago, Nancy and Leonard
Florsheim family fund, NIH grants (R01GM135504, R01DK118266,
R01GM062970, RO1AR078555) andNSF1808087. S.Kh. laboratory is supported
by a grant from Fondation ARC, PGA1RF2019208471 as well as by ANR Episperm4 program. Additional supports were from: Plan Cancer (CH7-
INS15B66, C7H-KIC19N30-IAB and ASC16012CSA), INCa-IReSP (R19051CC) and
the ‘University Grenoble Alpes’ ANR-15-IDEX-02 (SYMER and LIFE). The
Structural Genomics Consortium is a registered charity (1097737) that receives
funds from AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada
Foundation for Innovation; Eshelman Institute for Innovation; Genentech,
Genome Canada through Ontario Genomics Institute [OGI-196]; EU/EFPIA/
OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking
[EUbOPEN grant 875510]; Janssen, Merck & Co.; Novartis Pharma AG; Pfizer, São
Paulo Research Foundation-FAPESP, Takeda and the Wellcome Trust.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|1 区生物学
小类|1 区细胞生物学
最新[2023]版:
大类|1 区生物学
小类|2 区细胞生物学
第一作者:
第一作者机构:[1]Ben May Department for Cancer Research, The University of Chicago, Chicago,IL, USA
通讯作者:
推荐引用方式(GB/T 7714):
Kyle Delaney,Minjia Tan,Zhesi Zhu,et al.Histone lysine methacrylation is a dynamic post-translational modification regulated by HAT1 and SIRT2.[J].Cell discovery.2021,7(1):122.doi:10.1038/s41421-021-00344-4.
APA:
Kyle Delaney,Minjia Tan,Zhesi Zhu,Jinjun Gao,Lunzhi Dai...&Yingming Zhao.(2021).Histone lysine methacrylation is a dynamic post-translational modification regulated by HAT1 and SIRT2..Cell discovery,7,(1)
MLA:
Kyle Delaney,et al."Histone lysine methacrylation is a dynamic post-translational modification regulated by HAT1 and SIRT2.".Cell discovery 7..1(2021):122